Stakeholder Insight: HIV - A way of life

HIV is now considered a chronic, manageable disease. However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are becoming increasingly influential in product choice. Consequently the development of new products which offer limited improvements in efficacy but better convenience and tolerability has changed prescription practices.

Scope

> Analysis of current treatment regimens and unmet needs, based on a survey of 180 physicians in the seven major pharma markets around the world

> Current epidemiology of HIV in the seven major markets, including prevalence, age and gender splits, with analysis of diagnosis and chain of care

> A detailed examination of the numbers of patients on each line of therapy, which drugs they are taking and for what reasons is provided

> An assessment of key unmet needs within HIV and the changes in mortality since the introduction of HAART is included

Highlights

Increasing transmission by heterosexual contact suggests both an absence and/or ineffectiveness of HIV awareness and education programs. It also exposes more females to the HIV virus, leading to unique disease management issues.

The success of HAART in prolonging survival within the HIV population introduces new psychosocial challenges beyond pharmaceutical management. Age-related conditions, comorbidities and the desire to conceive call for a new multi-faceted pattern of patient care

Datamonitor physician research indicates that of 273,000 first-line treated individuals, globally 79% are now receiving fixed dosed combinations (FDCs). While guidelines and HIV specialists have embraced their convenience and simplicity, the unstructured nature of later lines of therapy requires increasing individualization

Reasons to Purchase

> Understand the unique disease management issues raised by increasing heterosexual transmission of HIV to females

> Identify opportunities for new patterns of patient care following the success of HAART in prolonging survival

> Explore unmet needs in HIV therapy, as identified by treating physicians, and including increased individualization in later-line therapy

Pages: 284

Published: October 2005

Format: PDF
Table of Contents
Price: $15,200.00 / GBP7,600.00

[ Home ] [ Up ] [ Store Home Page ] [ Info ] [ Search ] [ View Basket ] [ Checkout ] [ Send email ] [ Login ]